Skin diagnostics company DermTech files for a $25 million IPO
DermTech, which is developing non-invasive gene expression tests to diagnosis various skin conditions, filed on Friday with the SEC to raise up to $25 million in an initial public offering. The La Jolla, CA-based company, which was founded in 1995, plans to list on the NASDAQ under the symbol DMTK. Maxim Group LLC is the sole bookrunner on the deal. No pricing terms were disclosed.